Pioneering a New Era In Asthma Control
Our Advanced Candidate: Dexpramipexole
Who We Are
A New Approach
How Did We Get Here?
Phase 3 Development Program
News Releases
Publications
Presentations
05.01.23
Journal of Allergy and Clinical Immunology: Safety and efficacy of dexpramipexole in eosinophilic asthma (EXHALE) a randomized controlled trial.
Read More
08.04.18
American Society of Hematology: “Dexpramipexole: a new antieosinophil drug?”
01.01.18
American Society of Hematology: “Dexpramipexole as an oral steriod-sparing agent in hypereosinophilic syndromes”
The Laryngoscope: “Dexpramipexole Depletes Blood and Tissue Eosinophils in Nasal Polyps”
01.16.17
Elsevier: “The targeted eosinophil-lowering effects of dexpramipexole in clinical studies”
We use only necessary cookies to ensure our website can work correctly and to enhance your experience. For more information about the cookies we use, please see our Cookie Policy.